DE19975040I2 - Medikamente enthaltend Salmeterol und Fluticason - Google Patents

Medikamente enthaltend Salmeterol und Fluticason

Info

Publication number
DE19975040I2
DE19975040I2 DE1990605951 DE69005951C DE19975040I2 DE 19975040 I2 DE19975040 I2 DE 19975040I2 DE 1990605951 DE1990605951 DE 1990605951 DE 69005951 C DE69005951 C DE 69005951C DE 19975040 I2 DE19975040 I2 DE 19975040I2
Authority
DE
Germany
Prior art keywords
fluticasone
salmeterol
medications containing
containing salmeterol
medications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE1990605951
Other languages
English (en)
Other versions
DE69005951T2 (de
DE69005951D1 (de
Inventor
James Barry Douglas Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19975040(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE19975040I2 publication Critical patent/DE19975040I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE1990605951 1989-09-08 1990-09-07 Medikamente enthaltend Salmeterol und Fluticason Active DE19975040I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
DE19975040I2 true DE19975040I2 (de) 2006-07-13

Family

ID=27264677

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1990605951 Active DE19975040I2 (de) 1989-09-08 1990-09-07 Medikamente enthaltend Salmeterol und Fluticason
DE69005951T Expired - Lifetime DE69005951T2 (de) 1989-09-08 1990-09-07 Medikamente enthaltend Salmeterol und Fluticason.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69005951T Expired - Lifetime DE69005951T2 (de) 1989-09-08 1990-09-07 Medikamente enthaltend Salmeterol und Fluticason.

Country Status (20)

Country Link
EP (1) EP0416951B1 (de)
JP (1) JP3042867B2 (de)
AT (1) ATE99941T1 (de)
BE (1) BE1003053A3 (de)
CA (1) CA2024916C (de)
CH (1) CH680983C9 (de)
DE (2) DE19975040I2 (de)
DK (1) DK0416951T3 (de)
ES (1) ES2062392T3 (de)
FR (1) FR2651677B1 (de)
HK (1) HK18695A (de)
HU (1) HU211272A9 (de)
IE (1) IE65535B1 (de)
IL (1) IL95590A (de)
IT (1) IT1241996B (de)
LU (1) LU90392I2 (de)
NL (1) NL990012I2 (de)
NZ (1) NZ235221A (de)
PH (1) PH27594A (de)
SG (1) SG166294G (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
SK284889B6 (sk) 1998-11-13 2006-02-02 Jago Research Ag Použitie stearátu horečnatého v suchých práškových formuláciách na inhaláciu
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
ATE343374T1 (de) 1999-09-11 2006-11-15 Glaxo Group Ltd Fluticasonpropionat arzneizubereitung
EP1248597B1 (de) * 1999-12-24 2005-03-30 Glaxo Group Limited Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
EP1383786B1 (de) 2001-04-30 2008-10-15 Glaxo Group Limited Antiphlogistische 7.beta.-carbothioate esterderivate von androstan mit einer 17.alpha.-zyklischen estergruppe
ES2316599T3 (es) 2001-09-14 2009-04-16 Glaxo Group Limited Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
AU2003205855A1 (en) † 2002-02-04 2003-09-02 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1757281A3 (de) * 2002-02-04 2009-07-15 Glaxo Group Limited Zubereitung zur Inhalation enthaltend ein Glucocorticoid und einen Beta 2-Adrenorezeptor Agonisten
CA2477714C (en) * 2002-03-04 2011-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
JP4755495B2 (ja) 2002-12-12 2011-08-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 組合せ医薬品
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
DK1658063T3 (da) 2003-08-06 2014-05-12 Galephar M F Fordelagtige kombinationer til inhalering af nacystelyn og bronkodilatorer
RU2006136025A (ru) * 2004-03-12 2008-04-20 Сипла Лимитед (In) Ингаляционные композиции
DK1616592T3 (da) 2004-07-16 2011-01-10 Almirall Sa Inhalator til administration af lægemidler i pulverform og en pulverpatron til anvendelse sammen med denne inhalator
PL2063940T3 (pl) 2006-12-22 2012-06-29 Almirall Sa Urządzenie inhalacyjne do leków w postaci sproszkowanej
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
PL3106149T3 (pl) 2009-05-29 2020-06-01 Pearl Therapeutics, Inc. Kompozycje do płucnego dostarczania długo-działających antagonistów muskarynowych i długo-działających agonistów receptora beta-2 adrenergicznego oraz powiązane sposoby i układy
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
KR20160003183A (ko) * 2013-04-29 2016-01-08 사노피 에스에이 흡입식 약학적 조성물 및 그를 포함하는 흡입기 장치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
FR2651677B1 (fr) 1993-08-06
ES2062392T3 (es) 1994-12-16
BE1003053A3 (fr) 1991-11-05
EP0416951B1 (de) 1994-01-12
CA2024916C (en) 2002-07-09
FR2651677A1 (fr) 1991-03-15
IT9048260A1 (it) 1992-03-07
SG166294G (en) 1995-06-16
HK18695A (en) 1995-02-17
IT1241996B (it) 1994-02-02
PH27594A (en) 1993-08-31
HU211272A9 (en) 1995-11-28
IE903256A1 (en) 1991-03-13
IE65535B1 (en) 1995-11-01
NL990012I1 (nl) 1999-07-01
LU90392I2 (fr) 1999-06-28
CH680983C1 (de) 2008-06-25
CH680983C9 (de) 2008-08-15
JPH03167120A (ja) 1991-07-19
IL95590A (en) 1996-06-18
CA2024916A1 (en) 1991-03-09
DE69005951T2 (de) 1994-05-26
NZ235221A (en) 1992-11-25
ATE99941T1 (de) 1994-01-15
EP0416951A1 (de) 1991-03-13
IT9048260A0 (it) 1990-09-07
CH680983A5 (de) 1992-12-31
JP3042867B2 (ja) 2000-05-22
IL95590A0 (en) 1991-09-16
DE69005951D1 (de) 1994-02-24
DK0416951T3 (da) 1994-02-14
NL990012I2 (nl) 1999-09-01

Similar Documents

Publication Publication Date Title
DE19975040I2 (de) Medikamente enthaltend Salmeterol und Fluticason
DE69002718D1 (de) Medikamente.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
CA2123909A1 (en) New combination of formoterol and budesonide
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
HU9202808D0 (en) Improvement of down-regulqtion of autoimmunic diseases by means of oral dosing of autoantigenes
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69918961D1 (de) Verbesserte inhalationspräparate
MY111155A (en) Medicaments
RU93003456A (ru) Лекарственный препарат
RU93003454A (ru) Лекарственный препарат